KU Hematology & Medical Oncology Review 2019

 

KU Hematology & Medical Oncology Review 2019
Avatar

KU ASCO 2019 Long-Term Survival of Dabrafenib Plus Trametinib in Metastic BRAF-Mutated Melanoma & PR and Survival of Neoadjuvant Therapy

By KU Hematology & Medical Oncology Review 2019 FEATURING Gary Doolittle
By KU Hematology & Medical Oncology Review 2019 FEATURING Gary Doolittle
240 views
August 22, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

19:25
Pfizer Hematology

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

Feat. A. Ip

Featured Video

20:14
Exelixis

Hypothetical Patient Case: RAI-R Metastatic Differentiated Thyroid C…

Feat. R. Alter, R. Shameem
Skin
12:46

KU ASCO 2019 Update on Surgical Treatment of Melanoma & Adjuvant Ipi…

KU Hematology & Medical Oncology Review 2019

G. Doolittle

68 views
07:50

KU ASCO 2019 Updates on Trial Discussing Nivolumab + Ipilimumab in M…

KU Hematology & Medical Oncology Review 2019

G. Doolittle

258 views
08:44

KU ASCO 2019 Long-Term Survival of Dabrafenib Plus Trametinib in Met…

KU Hematology & Medical Oncology Review 2019

G. Doolittle

240 views